You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Fig. 2

Swim lane plot demonstrating time on combination of kinase inhibitor therapy and pembrolizumab: The figure below describes the timeline on combination of kinase inhibitor therapy and pembrolizumab. Patient no. 11 was on trametinib with pembrolizumab. She developed Grade 3 rash on this combination and was switched to everolimus as a single agent. Seven patients (58%) died while on this therapy. Of these, four patients discontinued treatment due to adverse events and opted for hospice. The figure below shows that these patients continued to derive some survival benefit from exposure to this combination therapy and lived for a median of 4.25 months (range 2.29–5.4 months) after discontinuing all treatment for their cancer

Back to article page